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Hypomorphic Temperature-Sensitive Alleles
of NSDHL Cause CK Syndrome
Keith W. McLarren,1,2,3,21 Tesa M. Severson,4,21 Christe`le du Souich,1,2,3,21 David W. Stockton,5
Lisa E. Kratz,6 David Cunningham,7 Glenda Hendson,8 Ryan D. Morin,4 Diane Wu,4 Jessica E. Paul,4
Jianghong An,4 Tanya N. Nelson,8 Athena Chou,1,2 Andrea E. DeBarber,9 Louise S. Merkens,10
Jacques L. Michaud,11 Paula J. Waters,8 Jingyi Yin,1 Barbara McGillivray,1,2,3 Michelle Demos,12
Guy A. Rouleau,11 Karl-Heinz Grzeschik,13 Raffaella Smith,14 Patrick S. Tarpey,14 Debbie Shears,15
Charles E. Schwartz,16 Jozef Gecz,17 Michael R. Stratton,14 Laura Arbour,1 Jane Hurlburt,1
Margot I. Van Allen,1,2 Gail E. Herman,7 Yongjun Zhao,4 Richard Moore,4 Richard I. Kelley,6
Steven J.M. Jones,4,18 Robert D. Steiner,19 F. Lucy Raymond,20 Marco A. Marra,4
and Cornelius F. Boerkoel1,2,3,*
CK syndrome (CKS) is an X-linked recessive intellectual disability syndrome characterized by dysmorphism, cortical brain malforma-
tions, and an asthenic build. Through an X chromosome single-nucleotide variant scan in the first reported family, we identified linkage
to a 5 Mb region on Xq28. Sequencing of this region detected a segregating 3 bp deletion (c.696_698del [p.Lys232del]) in exon 7 of NAD
(P) dependent steroid dehydrogenase-like (NSDHL), a gene that encodes an enzyme in the cholesterol biosynthesis pathway. We also
found that males with intellectual disability in another reported family with an NSDHL mutation (c.1098 dup [p.Arg367SerfsX33])
have CKS. These two mutations, which alter protein folding, show temperature-sensitive protein stability and complementation in
Erg26-deficient yeast. As described for the allelic disorder CHILD syndrome, cells and cerebrospinal fluid from CKS patients have
increased methyl sterol levels. We hypothesize that methyl sterol accumulation, not only cholesterol deficiency, causes CKS, given
that cerebrospinal fluid cholesterol, plasma cholesterol, and plasma 24S-hydroxycholesterol levels are normal in males with CKS. In
summary, CKS expands the spectrum of cholesterol-related disorders and insight into the role of cholesterol in human development.X-linked intellectual disability (XLID) disorders account
for 16% of all intellectual disabilities in males.1 This high
frequency arises in part because males, unlike females,
have only one X chromosome. To date, 91 genes involved
in XLID have been cloned with demonstrated causative
mutations and another 35 XLID syndromes have been
mapped.2 Despite this progress, ~50% of affected families
lack an identified causative mutation and thus remain
undiagnosed.3
CK syndrome (CKS) is a recently described XLID disorder
named after the first reported patient.4 It is characterized
by mild to severe cognitive impairment, seizures begin-
ning in infancy, microcephaly, cerebral cortical malforma-
tions, and a thin body habitus.4 Distinctive features
include downslanting palpebral fissures, a high nasal
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ings (Figure S1, available online). Affected males also have
behavior problems, including aggression, attention deficit
hyperactivity disorder, and irritability.4
Using DNA from the first described family,4 we per-
formed an X chromosome single-nucleotide variant
(SNV) scan of family members giving consent to the
protocol (H07-02142), approved by the clinical research
ethics board at the University of British Columbia. We
identified linkage to Xq28 (Figure 1). Two-point linkage
analysis was performed with MLink from the FASTLINK
software package, version 4.0P,5 and the Allegro program,
version 1.1b.6 Multipoint linkage analysis was performed
with the Allegro program. The maximum two-point and
multipoint LOD scores were, respectively, 1.43 (q ¼ 0)
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Figure 1. Family 1 Pedigree, Linkage Analysis, DNA Sequencing Results, and NSDHL Mutation
(A) A five-generation family segregating CKS in males.4 The propositus is indicated by an arrow. Affected males are indicated in black.
Female carriers of the NSDHLmutation are indicated by a black dot in the center. Females I-2, II-2, and II-4 are assumed obligate carriers.
X chromosome linkage analysis identified a critical disease locus on Xq28 (red bar). The maximum two-point (1.43, q ¼ 0) and multi-
point (2.29, q ¼ 0) LOD scores were at marker rs941400 (highlighted).
(B) The SNVs (left) and indels (right) identified in each individual in short-read analysis. SNVs and indels affecting the coding sequence
are in parentheses; those events unique to the individual are indicated in red. The single indel unique to the propositus V-3 was in
NSDHL.
(C) Diagram of the NSDHL showing coding (orange) and noncoding (light blue) exons. The exons showing homology to the steroid
dehydrogenases are underlined in red.
(D) Chromatograms showing the NSDHL c.696_698delGAA mutation segregating with CKS in family 1. The predicted protein transla-
tion is shown above chromatograms.
(E) Lysine 232 is not conserved across species but lies between well-conserved amino acids.microsatellite analysis narrowed the interval to 5 Mb,
marker DXS1684 to the telomere (Figure 1). Analysis of
the 36.5 NCBI build of the human genome sequence
revealed 133 positional candidate genes, expressed
sequence tags (ESTs), and noncoding RNAs annotated
within this region.
By long-range PCRwe amplified1,535,643 bpof genomic
sequence containing 111,381 bp of coding sequence and
used Illumina reversible terminator-based sequencing to
sequence the amplicons. Sufficient sequence coverage
for unambiguously identifying variants was obtained for
85.3%, 80.6%, and 87.5% of the coding sequence in indi-906 The American Journal of Human Genetics 87, 905–914, Decembviduals V-3, III-4, and IV-11, respectively (Figure S2). Anal-
ysis identified a total of 6200SNVs and581 indels (Figure 1).
Of the SNVs, 5106 were not found in four reference
genomes.7–10 Capillary resequencing of 44,925 bp
confirmed 86% of the SNV and indel observations. Of the
1347 SNVs and one indel unique to the proband, one SNV
and one indel met the following criteria: (1) is absent
from dbSNP, (2) is confirmed by capillary sequencing, (3)
changes an amino acid change, and (4) segregates with
CKS. The SNV was a mutation in F8 (c.1064G>A
[p.Arg355Gln]), which encodes the blood coagulation
factor 8 associated with hemophilia A. However, thiser 10, 2010
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Figure 2. Family 2 Pedigree and NSDHL Mutation
(A) A three-generation family identified by Tarpey et al.11 segregating CKS4 in males. The propositus is indicated by an arrow. Affected
males are indicated in black. Female carriers of the NSDHLmutation are indicated by a black dot in the center. X chromosome linkage
analysis identified a critical disease locus on Xq28 with a LOD score of 1.06.
(B) Chromatograms showing the NSDHL c.1098dup mutation segregating with CKS.
(C) The predicted protein translation showing that the frameshift extends the protein past the native stop codon and into the 30 untrans-
lated region.mutationwas considered clinically irrelevant because these
males do not have bleeding problems. The indel was in
exon 7 of NAD(P) dependent steroid dehydrogenase-like
(NSDHL [MIM 300275]) (NM 015922.1:c.696_698del
[p.Lys232del]) (Figure 1). The NSDHL mutation was
not observed in 150North American control chromosomes
or in the 357 genomes evaluated for indels as part of the
1000 Genomes Project. We did not observe NSDHL
mutations among 79 males (58 syndromic and 21 nonsyn-
dromic) with intellectual disability (Table S1). During
the course of our studies, however, Tarpey et al.11 reported
that 1 of 208 families with X-linked intellectual disability
had an NSDHL mutation (c.1098dup [p.Arg367SerfsX33,
reported as p.R367fsX31 by Tarpey et al.11]) (Figure 2).
Careful clinical evaluation of this family by F.L.R. showed
that the p.Arg367SerfsX33 mutation, which extends the
protein past the native stop codon and into the 30 untrans-
lated region (Figure 2), also causes CKS in this family
(Figure 3).The AmericanThe NSDHL enzyme, which localizes to the surface of
the endoplasmic reticulum and lipid droplets, is a C4
demethylase involved in postsqualene cholesterol biosyn-
thesis.12–14 Because CKS males and their mothers had
normal plasma cholesterol, steroid hormone levels, and
lipoprotein profiles (Table 1), we cultured lymphoblastoid
cells expressing p.Lys232del or p.Arg367SerfsX33 NSHDL
in cholesterol-poor medium and measured sterols as
described.15 Although of lesser severity, the sterol aberra-
tions were similar to those reported for the allelic disorder
congenital hemidysplasia with ichthyosiform nevus and
limb defects syndrome (CHILD [MIM 308050]) (Figure 4)
(R.I.K., unpublished data) and in mice with Nsdhl muta-
tions.16 The aberrations include accumulation of 4-methyl
sterol intermediates, 4,4-dimethyl sterol intermediates,
lathosterol, and desmosterol.16
NSDHL mutations associated with CHILD are presumed
to eliminate or greatly decrease NSDHL function be-
cause they include nonsense, frameshift, and deletionJournal of Human Genetics 87, 905–914, December 10, 2010 907
Figure 3. Males Affected with CKS
(A) Affected males from family 1 (V-3 and IV-8) hemizygous for the c.696_698del (p.Lys232del) NSDHL mutation and from family
2 (III-1, III-4, III-7, and II-7) hemizygous for the c.1098dup (p.Arg367SerfsX33) NSDHL mutation.
(B) Summary of clinical features in males with CKS from families 1 and 2.mutations.17 To test this, we assessed NSDHL expression in
fibroblasts cultured from the affected skin of CHILD
patients. Consistent with the nonsense mutations causing
either nonsense-mediated mRNA decay or rapid degrada-
tion of a truncated protein, the cultures were a mosaic of
cells with and without NSDHL expression (Figure S3).
Using the Swiss-Model server18 to predict the tertiary
structure of NSDHL, we found that p.Lys232del disrupts
a b-pleated sheet (Figure 4). By immunoblotting, the
steady-state level of NSDHL in patient cells expressing
either p.Lys232del or p.Arg367SerfsX33 NSDHL was mark-908 The American Journal of Human Genetics 87, 905–914, Decembedly reduced despite comparable mRNA levels as measured
by qRT-PCR (Figure 4). Deletion of the analogous amino
acid Glu221 from mouse Nsdhl confirmed a stabilizing
role for this amino acid when the protein was expressed
in HEK293 cells (Figure S4). Also, immunoblotting for
p.Lys232del and p.Arg367SerfsX33 NSDHL expressed in
HEK293 cells detected low or undetectable steady-state
levels unless the proteosome was inhibited with MG132
(Figure 4).
The p.Lys232del and p.Arg367SerfsX33 NSDHL had
a distribution similar to that of wild-type NSDHL ander 10, 2010
Table 1. Serum Cholesterol, Lipoprotein, and Sterol Profiles for Members in Family 1 and Family 2
p.Lys232del NSDHL Positive
p.Arg367SerfsX33
NSDHL Positive p.Lys232del NSDHL Negative
III-2 III-5 III-8 IV-2 IV-6 IV-7 IV-8 V-1a V-2 V-3 II-2 III-1 IV-10 IV-11
Sex F F F F M F M F F M F M F M
Age (yrs) 67 53 65 43 11 16 22 23 21 19 41 21 42 44
X inactivation ratiob 69:31 89:11 86:14 71:29 NR NR NR 70:30 90:10 NR NR NR NR NR
Cholesterol (mg/dL) 183.7 384.4 230.9 181.0 164.3 225.1 228.5 266.8 169.4 138.8 176.7 182.5 238.2 176
24S (ng/ml) 48.5 31.1 NR 43.6 NR 80.8 70.9 62.1 65.6 46.4 NR NR NR 40.6
Lipoproteins
LDL (mg/dL) 107.5 266.1 129.9 95.9 99.0 150.4 163.6 139.2 99.8 86.2 106 115 147.3 77.7
HDL (mg/dL) 49.1 43.7 46.4 75.0 56.1 45.6 42.5 81.2 56.1 29.8 47.9 22.4 70.4 63.4
Steroids
Estradiol (pg/ml) 27.2 NR 24.2 217.9 13.3 97.0 34.1 NR 249.8 20.4 NR NR 38.7 NR
Testosterone (ng/ml) 0.7 < 0.2 0.60 0.4 < 0.2 0.8 6.8 1.6 0.4 3.8 NR NR 0.69 NR
DHEAS (ug/dl) 106.8 29.5 77.4 117.9 70.0 333.6 187.9 62.6 143.7 138.8 NR NR NR NR
Cortisol (ug/dl) NR 10.7 11.9 14.1 9.7 10.8 17.9 24.3 14.6 NR NR NR NR NR
Progesterone (ng/ml) NR <0.2 NR 21.4 NR 4.1 NR 109.1 1.89 NR NR NR NR NR
Abbreviations are as follows: 24S, 24S-hydroxycholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; DHEAS, 5-Dehydroepiandrosterone
sulfate; F, female; M, male; NR, not reported or not checked.
Normal value ranges are as follows:
Cholesterol: adult male (110.2–220.4); adult female (162.4–201.8); pediatric male (125.7–230); pediatric female (106.3–216.6).
24S: males and females ages 11–70 years (30.1–105.9).
LDL: adult male (58–116); adult female (58–131.5); pediatric male and female (< 110).
HDL: adult and pediatric male and female (> 34.8).
Estradiol: adult male (15–45); adult female (30–450); adult postmenopausal female (< 59.9); prepubertal (< 10.9).
Testosterone: adult male (2.8–8.8); adult female (0.1–0.8); prepubertal (< 0.2).
DHEAS: adult female (33.2–431); prepurbertal (7.4–66.3).
Cortisol: morning levels; adult male/female (5–25).
Progesterone: adult postmenopausal females (< 1); adult preovulatory females (< 1); adult midcycle females (5–20); adult females in third trimester of pregnancy
(48.4–425).
a Individual V-1 was 32 wks pregnant at the time of blood work. Reference ranges for total cholesterol and lipoproteins are based on those reported by Piechota
and Statszewski.40 All values were within the normal range for pregnancy in the third trimester.
b X inactivation ratio for an additional p.Lys232del NSDHL-positive female (IV-9) is 58:42; for a p.Lys232del NSDHL-negative female (V-4), the ratio is 36:64.partially colocalized with the endoplasmic reticulum
protein calnexin (Figure 4). To test whether the mutant
protein retained enzymatic activity, we assessed comple-
mentation in S. cerevisiae deficient for the NSDHL ortholog
Erg26.19 The appropriate cDNAs were cloned into the pAG-
416-GPD-DEST vector and inserted as single copies into the
yeast strain SGD200, which is deficient for Erg26.13 Inter-
estingly, both p.Lys232del and p.Arg367SerfsX33 NSDHL
complemented at 30C (Figure 4). Immunoblotting
detected protein levels comparable to those of wild-type
NSDHL at 30C but detected little mutant protein when
the yeast were grown at 37C (Figure 4). Therefore, at
a permissive temperature of 30C, the mutant NSDHL
proteins are able to correctly fold and function at a level
comparable to wild-type, whereas at the restrictive temper-
ature of 37C, abnormal folding of the mutant proteins
results in protein degradation. Given that NSDHL muta-
tions associated with CHILD syndrome and the Nsdhl
loss-of-function alleles found in Bpa mice do not show
complementation at the permissive temperature,19 weThe Americanconclude that the p.Lys232del and p.Arg367SerfsX33
mutations are temperature-sensitive hypomorphic alleles
of NSDHL. From this, we postulate that these hypomor-
phic alleles retain sufficient function to allow survival of
males and to mitigate the severe features of CHILD
syndrome, particularly in cooler tissues such as skin.
Because the developing brain synthesizes cholesterol de
novo,20 we used in situ hybridization and immunohisto-
chemistry to assess NSDHL expression and NSDHL locali-
zation, respectively, in the mouse and human brain. The
mouse and human tissues were obtained in accordance
with protocols approved by the University of British
Columbia’s ethical review board and institutional policies.
In both species, cortical neurons and glia express NSDHL
throughout development (Figure S5). Therefore, we
hypothesized that deficiency of NSDHL could cause the
cortical brain malformations observed in males with CKS
(Figure 5).4 Indeed, histopathological studies of embryonic
day 10.5 (E10.5) forebrains from male mice with a Bpa8H
loss-of-function allele of Nsdhl19 showed a thin andJournal of Human Genetics 87, 905–914, December 10, 2010 909
Figure 4. NSDHL Mutations Associated with CKS
(A) Comparative sterol profiles of a CKSmale (V-3) of family 1 and an unaffectedmale. The sterol abnormalities have the same pattern as
those observed in CHILD. Sterols were measured in lysates from lymphoblastoid cells cultured in cholesterol poor medium for 3 days.
K232del ¼ Lys232del. Error bars represent one standard deviation.
(B) Comparative sterol profiles of a CKS male (III-1) of family 2 and an unaffected male. Again, the sterol abnormalities have the same
pattern as those observed in CHILD. Sterols weremeasured in lysates from lymphoblastoid cells cultured in cholesterol-poor medium for
3 days. R367SfsX33 ¼ Arg367SerfsX33. Error bars represent one standard deviation.
(C) Predicted tertiary structure of wild-type NSDHL (blue) and p.K232del NSDHL (ochre). The protein structures are superimposed to
highlight differences. The region between G229 and T239 (white box) is enlarged below; K232 is shown on the wild-type protein in
the enlargement.
(D) Immunoblot showing NSDHL expression in unaffected male (Cnt) and p.K232del primary skin fibroblasts (left) and in unaffected
male (Cnt) and pR367SfsX33 lymphoblastoid cells (right).
(E) Quantitative real-time PCR measurement of NSDHLmRNA steady-state levels in unaffected male (Cnt) and p.K232del primary skin
fibroblasts (left) and in unaffectedmale (Cnt) and p.R367SfsX33 lymphoblastoid cells (right). Error bars represent one standard deviation
for three biological replicates.
(F) ImmunoblotdetectionofendogenousNSDHLandV5-taggedNSDHLinHEK293T-Rexcells transfectedwith tetracycline-inducibleexpres-
sionconstructs.After selectionof stablecell lines, expressionof therespectiveNSDHLwas inducedwithtetracycline.Fordeterminingwhether
mutant proteinsweredegradedby the proteosome, protein levelsweremeasured before and after inhibition of theproteosomewithMG132.
(G) Indirect immunofluorescent subcellular localization of V5-tagged NSDHL (green) in HEK293T-REx cells after tetracycline induction and
proteosome inhibitionwithMG132.Anti-Calnexin (Cal, red)wasused to identify theendoplasmic reticulum.Cellswere counterstainedwith
DAPI (Scale bar represents 10 mm).
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Figure 5. Mutant NSDHL Localization and Functionality
(A) Neuropathology of E10.5 male wild-type (wt) (iiv) and Nsdhlmutant (Bpa8H, v–viii,) mice. (i and v) Whole mounts of the embryos
(scale bar represents 1mm). (ii and vi) Serial 7 mmhorizontal sections through the forebrain at the level of the lens and optic cup stained
with hematoxylin and eosin (scale bar represents 50 mm); the black box represents the area of highermagnification shown in panels iii–iv
and vii–viii. Sections of forebrain stained for proliferation by BrdU incorporation (iii and vii) or for apoptosis by TUNEL-labeling (iv and
viii) (scale bar represents 20 mm). The tissue was counterstained with hematoxylin.
(B) Quantification of dorsal anterior forebrain thickness, proliferation, and apoptosis in wt and Bpa8H male forebrains. The left graph
shows the relative thickness of the dorsal anterior forebrain (FB) measured in four adjacent sections (wt, n ¼ 6; Bpa8H, n ¼ 3;
p ¼ 0.32). The middle graph shows the percentage of BrdU-positive cells (wt, n ¼ 6; Bpa8H, n ¼ 3; p ¼ 0.16). The right graph shows
the percentage of TUNEL-positive (apoptotic) cells (wt, n ¼ 6; Bpa8H, n¼ 3; p ¼ 0.48). In all graphs, the error bars represent one standard
deviation.
(C) MRI scan of the proband V-3, age 6 yrs, showing a simplified gyral pattern in the frontal and parietal cortex (arrows).disorganized cortex and, as measured by TUNEL and BrdU
incorporation, significantly increased numbers of
apoptotic cells as well as increased cellular proliferation
(Figure 5). This paradoxical observation can be explained
by the toxic and proliferative effects of methylsterols
(L.E.K. and R.I.K., unpublished data).
Fromtheseobservations,wehypothesized that accumula-
tion of methylsterols, not cholesterol deficiency alone,
causes CKS. Three patient observations support this: (1) as
measured by isotope dilution liquid chromatography-
tandemmass spectrometry,21 postnatal plasma24S-hydrox-
ycholesterol levels, a measure of brain cholesterol
turnover,22 did not differ from controls for absolute 24S-
hydroxycholesterol levels or 24S-hydroxycholesterol:
cholesterol ratios (Table 1); (2) the cerebrospinal fluid
(CSF) cholesterol level of one affected male was normal,
whereas his CSF methylsterol levels were elevated (data
not shown); and (3) the phenotype and neuropathology
ofmaleswithCKS are distinctlydifferent than that observed
in humans or mice with deficiency of sterol delta-7-reduc-
tase,23,24 the last step in the synthesis of cholesterol.25
Accumulation of substrate and consequent toxicity, with
or without cholesterol deficiency, also explains the diver-
sity of phenotypes observed with defects of cholesterol(H) Complementation at 30C in yeast deficient for Erg26, the NSDHL
expression plasmid without an insert was used as the negative control
p.R367SfsX33) human NSDHL in Erg26-deficient yeast grown at 30C
control.
The Americanbiosynthesis. These include Greenberg dysplasia (MIM
215140), mevalonic aciduria (MIM 610377), X-linked
dominant chondrodysplasia punctata (CDPX2 [MIM
302960]), lathosterolosis (MIM 607330) and desmosterolo-
sis (MIM 602398), as well as Smith-Lemli-Opitz syndrome
(SLOS [MIM 270400]), CHILD syndrome, and CKS.26,27
Similarly, in Insig double-knockoutmice, the accumulation
of cholesterol precursors in the presence of normal choles-
terol levels causes phenotypes ranging from facial
clefting28 to hair-growth defects,29 and consistent with
this, the pathology is ameliorated or reversed by blocking
the pathway with HMG-CoA reductase inhibitors.28,29
Study of SLOS also implicates the accumulation of enzy-
matic substrates, not cholesterol deficiency alone, as the
cause of disease.26,30 First, cultured fibroblasts with
mutationspredicted tohavenoDHCR7activity can synthe-
size cholesterol at rates that can be as high as 50% of all
sterols; this suggests that cells have alternate pathways for
synthesizing cholesterol.30 Second, theoxidizedderivatives
of 7-dehydrocholesterol retard growth of cultured rat
embryos, are toxic to cultured cells, and induce gene-
expression changes similar to those observed in cells defi-
cient for 7-dehydrocholesterol reductase activity.26,31
Understanding the role of these substrates in humanortholog, bywt or mutantNSDHL (p.K232del or p.R367SfsX33). The
(Neg Cnt). Immunoblot detection of wt and mutant (p.K232del or
or 37C. 3-phosphoglycerate kinase (PGK) is shown as the loading
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Figure 6. Model of How NSDHL Mutations
Cause a Spectrum of Disease
Unimpeded cholesterol production allows
normal neurodevelopment. In contrast, reduced
flow or flux through the pathway because of
a hypomorphic NSDHL enzyme leads to dose-
dependent effects of cholesterol deficiency and/
or sterol precursor buildup in the brain. This
results in neurodevelopmental malformations
(CK syndrome). As the block becomes more
extreme, further loss of functional NSDHL leads
to severe developmental aberrations and cell
death, resulting in male lethality and CHILD
syndrome.biology is thus crucial to treating these disorders and under-
standing the role of cholesterol in human behavior.32,33
Alternatively, the anomalies of CKS might be attribut-
able, at least in part, to deficient hedgehog signaling as
has been suggested in SLOS30 and in studies of Nsdhl-defi-
cient mouse placentas.34 Autoprocessing of the hedgehog
protein requires cholesterol as a cofactor and covalent
adduct.35 Also, cells defective in cholesterol biosynthesis
have a defective response to Sonic hedgehog signaling
because of reduced Smoothened activity.36,37 In contrast
to SLOS or mutations of Sonic hedgehog, however, CKS
individuals do not have polydactyly, syndactyly, genital
anomalies, or, as judged by MRI, a rostral-caudal gradient
of neuropathology, the forme fruste of holoprosencephaly.
Thus, deficient hedgehog signaling does not fully explain
the pathology of CKS and again suggests a pathology
arising primarily from accumulation of methylsterols.
Interestingly, the pathology of CKS is also distinct from
that of CHILD syndrome. This disorder, which affects
females, is characterized by normal intellect, unilateral
ichthyosiform skin lesions typically involving only the
right side of the body, alopecia, ipsilateral limb defects
with epiphyseal stippling, and occasional internal malfor-
mations.38 Mutations of NSDHL causing CHILD syndrome
are presumed to be lethal to males on the basis of the skew-
ing of the sex ratio and mouse models.16,17 Mouse models
have skewing of X inactivation as adults (Figure S6).39 Also,
we found that fibroblast cultures from affected skin of
three CHILD patients had X inactivation ratios of 77:23,
96:4, and 92:8 (Figure S6). In the mouse model, the devel-
opment of skewing is progressive, suggesting that the
pathology of CHILD syndrome arises from cell death.39
In contrast, mothers carrying an NSDHLmutation causing
CKS have X inactivation ratios ranging from 90:10 to 58:42
(Table 1), a range common in the general population; this
provides additional in vivo support that the NSDHL muta-
tions observed with CKS are hypomorphic.912 The American Journal of Human Genetics 87, 905–914, December 10, 2010In summary, CKS expands the pheno-
types associated with NSDHL mutations.
In CHILD syndrome17 and in the bare
patches and striated Nsdhl mutant mice,16
there is male lethality and tissue deficiency
among carrier females. In contrast, maleswith CKS survive, and their mothers have no physical
abnormalities.4 This diversity of phenotypes arising from
dysfunction of NSDHL is likely the consequence of varia-
tions in flux through the cholesterol biosynthesis pathway
(Figure 6). Our findings provide an entry point for further
dissection of the role of cholesterol synthesis intermediates
in human development.
Supplemental Data
Supplemental data include six figures and one table and can be
found with this article online at http://www.cell.com/AJHG/.
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